Fedratinib

Drug Profile

Fedratinib

Alternative Names: SAR-302503; TG-101348

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator TargeGen
  • Developer Sanofi
  • Class Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera; Solid tumours

Most Recent Events

  • 18 Nov 2013 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 18 Nov 2013 Discontinued - Phase-II for Essential thrombocythaemia in France (PO)
  • 18 Nov 2013 Discontinued - Phase-II for Essential thrombocythaemia in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top